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Abstract 24 
Thin and erodible polymeric films were developed as potential ocular drug delivery systems to 25 
increase drug retention on the eye with the aim of improving bioavailability and achieving 26 
controlled drug release. Two biocompatible film forming polymers, hyaluronic acid (HA) and 27 
hydroxypropyl methylcellulose (HPMC), which are currently used as thickening agents in eye 28 
drops were employed. Two different films were prepared (i)  as single polymer and (ii) as 29 
composite formulations by solvent casting method, incorporating glycerol (GLY) as plasticizer 30 
and timolol maleate salt (TM) as model glaucoma drug. After preliminary optimization of 31 
transparency and ease of handling, the formulations were further characterized for their 32 
physicochemical properties. No indication of significant drug-polymer or polymer-polymer (in 33 
composite films) interaction was observed from FTIR results while evaluation by IR mapping 34 
revealed uniform distribution of drug throughout the films. Amorphization of TM in the film 35 
matrix was confirmed by both DSC and XRD. Swelling studies illustrated remarkable swelling 36 
capacity of HA in comparison with HPMC which directly affected the drug release profiles, 37 
making HA a suitable polymer for controlled ocular drug delivery. Tensile and mucoadhesion 38 
properties confirmed higher elasticity and adhesiveness of HA while HPMC produced stronger 39 
films. The effect of sterilization by UV radiation on mechanical properties was also evaluated 40 
and showed no significant difference between the sterilized and non-sterilized films. The SEM 41 
results confirmed smoothness and homogeneity of film surfaces for all the formulations 42 
studied. The in vitro drug dissolution studies showed more extended release profiles of 43 
formulations containing HA. Cytotoxicity study (cell viability) using MTT assay on HeLa 44 
cells, confirmed that the single polymer and composite films are generally safe for ocular 45 
administration. The present work shows excellent film forming ability of HA and HPMC which 46 
can be used as single polymer or combined in composite formulations as potential topical 47 
ocular drug delivery platform to enhance drug retention on the ocular surface and therefore 48 
potential improved bioavailability. 49 
 50 
Keywords: Composite films, glaucoma, HPMC, hyaluronic acid, mucoadhesion, ocular 51 
delivery, timolol  52 
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1. Introduction 54 
Drugs administered using current conventional topical ophthalmic formulations such as eye 55 
drops tend to present poor bioavailability due to complex and unique anatomy, physiology and 56 
biochemistry of the eye. The sophisticated structure of the eye protects this sensory organ from 57 
the external environment, and presents significant limitations to the design of formulations for 58 
effective ocular therapy (Zafar et al., 2016).  59 
It has been reported that approximately 4% of the world’s population are visually 60 
impaired (Hashemi et al., 2017). This figure could significantly reduce if more efficient ocular 61 
dosage forms existed. Currently, instilling topical eye drops is the cheapest and most common 62 
method of administering drugs to treat ocular conditions. However, due to existing constraints, 63 
less than 5% of the applied dose is absorbed into the eye. This is because delivery of drug by 64 
eye drops is hampered by several anatomical and physiological barriers which limit 65 
bioavailability. These include blinking action, tear turnover, nasolacrimal drainage and low 66 
permeability of the cornea and/or biological barriers within the eye such as blood aqueous 67 
barrier (BAB) or blood retinal barrier (BRB) (Morrison and Khutoryanskiy, 2014). In chronic 68 
diseases, such as glaucoma, the drug bioavailability and subsequent therapeutic efficiency 69 
obtained with the current conventional dosage forms are considerably low. This results in the 70 
need to use other invasive dosage forms such as injections or surgical operations, which are 71 
painful and carry a very high risk of damaging the eye tissues and is normally not accepted by 72 
patients, especially the younger one. Studies have shown that almost 50% of glaucoma patients 73 
were found to be non-adherent to their currently available medication, 75% of the time (Aulton 74 
and Taylor, 2017). 75 
Glaucoma is a group of eye diseases associated with intraocular hypertension which 76 
causes damage to the optic nerve, and if left untreated will lead to blindness. Glaucoma is the 77 
second leading cause of blindness worldwide, and it is the world’s most common cause of 78 
irreversible blindness with 67 million people affected worldwide (Jons et al., 2017). Glaucoma 79 
is a progressive optic neuropathy caused by a slow degeneration of retinal ganglion cells and 80 
their axons, resulting in a distinct appearance of the optic disc (also known as cupping of the 81 
optic nerve) and an associated pattern of visual loss (Weinreb et al., 2014). In glaucoma, the 82 
aqueous humor drainage pathway becomes partially or completely blocked, so that fluid cannot 83 
easily drain out of the posterior chamber. This causes rapid increase of the pressure within a 84 
fixed space of the anterior chamber (intraocular pressure-IOP), causing ocular hypertension – 85 
which is defined as IOP greater than 21 mmHg (Jons et al., 2017). Most conventional drugs for 86 
glaucoma work by either increasing the aqueous humor outflow or reducing its production. 87 
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Timolol (TM), is a non-selective β-blocker from the family of adrenergic antagonists which 88 
reduces IOP by lowering aqueous humor formation and by enhancing the outflow facility 89 
(Zafar et al., 2016). All administered ophthalmic formulations require maintenance of visual 90 
clarity of the eye, prevention of irritation, infection and inflammation to the eye as well as 91 
being able to reach the site of action through the complicated physiological ocular barriers 92 
without damaging any healthy tissue (Morrison and Khutoryanskiy, 2014; Gulsen and 93 
Chauhan, 2004).  94 
Various attempts have been made in the past few years by different researchers to 95 
introduce novel approaches for ocular drug delivery as alternatives to topical eye drops, mainly 96 
using polymers to produce thin films, contact lenses, ocular inserts or nanoliposomes (Desai et 97 
al., 2018, Boateng and Popescu, 2016, Hui A., 2017, Mehta et al., 2017., Shafie and Rady 2012, 98 
Chavda et al., 2016, Jin et al., 2018, Wang et al., 2018). Other studies have reported the 99 
synthesis of acryloyl-quaternized poly(2-dimethylamino) ethyl methacrylate) (PDMAEMA) 100 
nanogels (Brannigan and Khutoryanskiy, 2017) and polymeric micelles (Mandal et al., 2017). 101 
However, the major drawback of micelles and nanogels have been the interference with patient 102 
vision and poor transparency of the formulation which was not investigated or mentioned in 103 
either studies.  104 
The use of nanoliposomes as ocular delivery system for glaucoma treatment has been 105 
reported with maximum drug release occurring in 4 hrs to reduce IOP. However, the IOP 106 
started to increase 6 hrs after administration of the liposomes (Jin et al., 2018 and Wang et al., 107 
2018). Desai and co-workers investigated release of TM from hyaluronic acid (HA) based 108 
semi-circular ocular inserts implanted onto contact lenses (Desai et al 2018). Despite prolonged 109 
release behavior achieved by using HA (one of the polymers being used in this study), essential 110 
performance characteristics such as the thickness, mucoadhesion and mobility of the contact 111 
lens on the ocular surface were not discussed. The thickness of commercially available contact 112 
lenses normally range between 70 - 90 µm and therefore addition of 40 µm thick insert on top 113 
of contact lenses could cause discomfort or mobility limitations on the mucosal surfaces of the 114 
eye. In addition, glaucoma is related to insufficient outflow of aqueous humor from posterior 115 
chamber of the eye, which is why majority of glaucoma patients experience dry eye and are 116 
often prescribed with eye drops to help lubrication of the ocular surface and to prevent damage 117 
to healthy eye tissues. Therefore, erodible and thin transparent films comprised of polymers 118 
available in the current moisturizing eye drops could potentially overcome the current existing 119 
challenges with topical ocular drug delivery in glaucoma. 120 
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Therefore, this study aims to develop novel TM loaded, erodible, and transparent 121 
composite thin films using mucoadhesive polymers [hydroxypropyl methylcellulose (HPMC) 122 
and hyaluronic acid (HA)], which are currently used as thickening agents in conventional eye 123 
drops, as potential drug delivery platforms for glaucoma. Ocular drug delivery using erodible 124 
mucoadhesive films offers several advantages over conventional dosage forms such as eye 125 
drops and other ocular drug delivery systems (ODDS). These advantages include a significant 126 
increase in ocular residence time, prolonged (controlled) release of the drug, accurate dosing, 127 
and maintaining lubrication of the eye by moisturizing effect, reduction in administration 128 
frequency and increased shelf time. 129 
Hyaluronic acid (HA), also known as hyaluronate, is a naturally derived anionic 130 
polysaccharide composed of repeating disaccharide units of N-acetyl-d-glucosamine (1-β-4) 131 
and d-glucuronic acid (1-β-3) (Calles et al., 2013). It has been widely used in the 132 
pharmaceutical industry over the past few years due to its natural biocompatibility and 133 
biodegradability, as well as low level of toxicity and immunogenicity. In addition, HA is a 134 
natural component of the eye fluid, as well as connective and epithelium tissues 135 
(Papakonstantinou et al., 2012). With its notable adhesive properties, HA is an outstanding 136 
choice as a carrier for ocular drug delivery, allowing the loaded drug to be released in a 137 
sustained pattern. HPMC is used extensively in the pharmaceutical industry as a film-forming 138 
agent, thickener, sustained-release, emulsifying and suspending agent in a wide variety of 139 
dosage forms, increasing their dispersity, toughness, sustained release properties and stability 140 
(Phadtare et al., 2014). Both HA and HPMC have widespread use in topical eye drops, mainly 141 
for their thickening property. Therefore, combining HA and HPMC will produce erodible thin 142 
ocular formulations possessing the excellent film forming properties of HPMC and exceptional 143 
adhesive characteristic of HA coupled with the biocompatible nature of both polymers with 144 
tissues in the human body. 145 
 146 
2. Materials and methods 147 
2.1. Materials 148 
Hydroxypropyl methylcellulose (HPMC) (molecular weight of 1261.45 g mol-1 and viscosity 149 
of 4,000 cP in water), glucose, gelatin, albumin and timolol maleate (TM) were purchased from 150 
Sigma Aldrich, (Gillingham, UK). Hyaluronic acid (HA) (molecular weight 2.6×106 Da) was 151 
purchased from Wisapple, (Beijing, China). Glycerol, sodium bicarbonate, potassium chloride, 152 
calcium chloride, sodium chloride, Dulbecco’s Modified Eagle’s Medium, fetal bovine serum, 153 
penicillin-streptomycin, MTT reagent and dimethyl sulfoxide were all purchased from Fisher 154 
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Scientific, (Loughborough, UK).  155 
 156 
2.2. Preparation of TM loaded ocular films 157 
Films were prepared using hyaluronic acid (HA) and hydroxypropyl methylcellulose (HPMC) 158 
as the primary polymers together with glycerol (GLY) as plasticizer (Table 1), using the solvent 159 
casting method, and incorporated with TM as model glaucoma drug.  160 
  The formulations included single polymer films prepared from 1.0% (w/v) HA (F1) and 161 
1.5% (w/v) HPMC (F2) gels, as well as 1% composite gel with 1:1 ratio of HPMC:HA (F3) 162 
and 2% composite gel with 3:1 ratio of HPMC:HA (F4). All formulations used 2:1 ratio by 163 
weight of total polymer: plasticizer following preliminary investigations testing the influence 164 
of various concentrations of plasticizer relative to polymer content based on the percent 165 
elongation values. Gel preparation was carried out by first dissolving TM (0.5% w/v) in twice-166 
distilled water. Once TM was thoroughly dissolved, appropriate amounts of GLY and the 167 
polymer powders (table 1) were added to the TM solution and the mixture was vigorously 168 
stirred at room temperature followed by drying in the oven at 40C to obtain the final films.  169 
 170 
 171 
2.3. Transparency 172 
Ocular drugs and delivery systems must be transparent and have zero interference with 173 
patient’s normal vision. Therefore, the films were evaluated for their clarity and transparency 174 
in three different ways. Primary physical transparency was judged by looking through the film 175 
to read the numbers on a standard measurement ruler. The evidence and result of this physical 176 
appearance judgement was recorded by taking digital images of each labelled film against a 177 
clearly numbered ruler. Secondly, the films were randomly shown to five human volunteers, 178 
and the participants were asked to score each film from 1 to 5, with 1 being completely 179 
transparent and 5 being completely opaque. The participants were asked to score as individuals 180 
in isolation (without any interactions) to avoid possible bias triggered by others’ opinion. 181 
Finally, the transparency of the films was also measured using UV spectrophotometer to 182 
determine the percentage light transmittance for each film at scan speed of 400 nm min-1 at 183 
three different wavelengths including UVB (290-320 nm), UVA (320-400 nm) and visible light 184 
(400-700 nm) (Fuentes et al., 2013). 185 
 186 
2.4. Physicochemical evaluation2.4.1 Thickness and weight 187 
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Film thickness was measured with a digital caliper gauge micrometer and determined at five 188 
different locations of each film including four corners and center. To measure the weight of the 189 
films, each film was cut into three small disks with 35 mm diameter and weighed using a digital 190 
balance from which average values were calculated. The weight and thickness results were also 191 
used in calculation of other physicochemical properties such as tensile and swelling studies 192 
respectively.  193 
2.4.2 Surface pH 194 
The surface pH was determined by placing the films in a closed Petri dish left to swell in 0.1 195 
mL of twice-distilled water at room temperature for 30 min. The insert was removed and placed 196 
in close contact with a digital pH meter to determine the surface pH (Priya et al 2014).  197 
2.4.3 Folding endurance  198 
The folding endurance of the films was determined by folding each film repeatedly at 180° 199 
angle of the plane at the same place until breakage. The films exhibiting folding endurance 200 
value of 300 or more were considered to have excellent flexibility (Karki et al 2016). 201 
 202 
2.5. Sterilization 203 
Exposure to UV radiation was used to sterilize the films prepared in this study. Each film was 204 
left in a closed Class II Biological Safety Cabinet (Triple Red, UK) equipped with Philips 205 
Germicidal Lamp (Guilford, Surrey, UK). This technique involves exposure of the samples to 206 
short-wave ultraviolet (also known as UV-C) within wavelength range of 100-280 nm for 24 207 
hrs. To confirm that the UV radiation did not significantly change the behavior of the films, 208 
the tensile and mucoadhesive properties of sterilized films were measured and compared with 209 
the corresponding non-sterile films. 210 
 211 
2.6. Swelling index study 212 
Swelling test was performed using simulated tear fluid (STF) prepared from sodium 213 
bicarbonate (192.40 mg L-1), potassium chloride (111.10 mg L-1), calcium chloride (2.30 mg 214 
L-1), sodium chloride (672.80 mg L-1), bovine serum albumin (669.00 mg L-1) and glucose 215 
(2.50 mg L-1) in twice-distilled water. The pH of STF was set to 7.4 and the fluid temperature 216 
was kept at 37 °C throughout the swelling test. Approximately 2 mL STF was poured on a 217 
previously weighed circular strip of the film (35 mm diameter) and allowed to swell. At specific 218 
time intervals, the STF was carefully removed from the film and the sample was weighed again. 219 
This was repeated until erosion of the films was observed (determined by the weight loss). The 220 
time interval for the measurements were every 2 min for the first 10 min and then every 5 min 221 
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until the films showed signs of erosion. Equation 1 was used to calculate the swelling capacity 222 
of each film (n = 3).   223 
𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 𝐼𝑛𝑑𝑒𝑥 = [
(𝑊𝑡− 𝑊0)
𝑊0
] × 100    (1) 224 
Where Wt is weight of swollen film at time t, and W0 is the original film weight at zero time. 225 
 226 
2.7. Tensile properties 227 
To measure the tensile properties, each film (n = 3)  was cut into standard dumb-bell shaped 228 
strips, which were placed between the texture analyzer (TA) (Stable Micro System, Surrey, 229 
UK) grips (probe) for stretching with a gauge length of 30 mm between each grip and stretched 230 
until breaking point, using a 5 kg load cell with 0.01 N trigger force. The pre-test speed and 231 
the test speed were both set at 1 mm sec-1, with the post-test speed at 10 mm sec-1. Equations 232 
(2 – 4) below were used to calculate the tensile strength, elastic modulus and percentage 233 
elongation respectively of each film. 234 
𝑇𝑒𝑛𝑠𝑖𝑙𝑒 𝑆𝑡𝑟𝑒𝑛𝑔𝑡ℎ =  
𝐹𝑜𝑟𝑐𝑒 𝑎𝑡 𝐹𝑎𝑖𝑙𝑢𝑟𝑒
𝐶𝑟𝑜𝑠𝑠−𝑆𝑒𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝐴𝑟𝑒𝑎
      (2) 235 
𝐸𝑙𝑎𝑠𝑡𝑖𝑐 𝑀𝑜𝑑𝑢𝑙𝑢𝑠 =  
𝑆𝑙𝑜𝑝𝑒
𝐶𝑟𝑜𝑠𝑠ℎ𝑒𝑎𝑑 𝑆𝑝𝑒𝑒𝑑 × 𝐶𝑟𝑜𝑠𝑠−𝑆𝑒𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝐴𝑟𝑒𝑎
    (3) 236 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝐸𝑙𝑜𝑛𝑔𝑎𝑡𝑖𝑜𝑛 =
𝐼𝑛𝑐𝑟𝑒𝑎𝑠𝑒 𝑖𝑛 𝐿𝑒𝑛𝑔𝑡ℎ (𝑒𝑙𝑜𝑛𝑔𝑎𝑡𝑖𝑜𝑛)
𝑂𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝐿𝑒𝑛𝑔𝑡ℎ
 ×  100   (4) 237 
 238 
2.8. In vitro mucoadhesion 239 
The adhesiveness of the films was also measured by TA using a cylindrical probe (35 mm 240 
diameter) and 5 kg load cell against set gelatin gel (20 g, 6.67% w/v) as the adhesive surface. 241 
To simulate ocular mucosa environment, 500 µL of STF was evenly spread on the surface of 242 
the gelatin prior to samples contacting the gelatin gel (Momoh et al, 2015). During testing, each 243 
film was cut into three (n = 3) 35 mm circular discs and attached to the end of the cylindrical 244 
probe and the probe activated to approach the Petri dish containing the gelatin gel. Each sample 245 
disc was left in contact with the moist gelatin surface for 60 sec to ensure complete contact, 246 
and then withdrawn at a speed of 1 mm min-1 and 0.01 N trigger force until complete 247 
detachment from the gelatin surface. Data obtained from the detachment of the sample was 248 
then used to calculate the mucoadhesion properties including peak adhesive force (PAF), total 249 
work of adhesion (TWA) and cohesiveness (distance travelled by probe before detachment) of 250 
the films.  251 
 252 
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2.9. Attenuated total reflectance (ATR) FTIR spectroscopy 253 
ATR-FTIR spectra of the films, starting materials and physical mixtures were acquired on a 254 
Perkin Elmer Two ATR-FTIR spectrometer (Seer Green, UK). Percentage transmittance (%T) 255 
mode was used in this study with 32 cm-1 resolution with scan speed of 0.2 over wavelength 256 
range of 450-4000 cm-1.  257 
 258 
2.10. IR microscopy and imaging 259 
IR maps and images were collected using a Nicolet iN 10 microscope (Thermo Fisher 260 
Scientific, Loughborough, UK) with liquid nitrogen cooled mercury cadmium telluride (MCT) 261 
detector and direct sampling with MicroTip ATR, Thermo Fisher Scientific (Loughborough, 262 
UK). The data were collected and analyzed by OMNIC Picta software. Different regions of 263 
each sample were analyzed by selecting random areas of the film using field view mosaic 264 
acquisition with 36 collection points to confirm distribution of TM throughout the film matrix. 265 
IR spectra were also obtained at each point together with 2D and 3D maps of the film for 266 
principal peaks of TM previously identified by ATR-FTIR spectroscopy. The system was set 267 
to transmittance mode and wavelength range of 450-4000 cm-1.  268 
 269 
2.11. Thermogravimetric analysis (TGA) 270 
Residual moisture content of the films was determined using TGA Q5000 SA (Delaware, 271 
USA). Samples (2-5 mg) were analyzed at temperature range of 25-300 °C with heating rate 272 
of 10 °C min-1 under constant stream of dry nitrogen flowing at 50 mL min-1 (ElShaer et al., 273 
2016). The plot of weight loss against temperature was obtained and analyzed by TA 274 
Instruments Universal Analysis 2000 software to determine the percentage residual moisture 275 
content of each sample.  276 
 277 
2.12. Modulated Differential Scanning Calorimetry (MDSC) 278 
The thermal profiles including the glass transition temperature (Tg) were measured for each 279 
film as well as pure starting materials using DSC Q2000 (Delaware, USA). Modulated DSC 280 
(MDSC) was used for the thin films to allow clearer illustration of glass transition. The DSC 281 
thermal analyzer was calibrated using high purity indium by initial cooling from 25 to -50°C 282 
at the rate of -10°C min-1. Accurately weighed samples (3-5 mg) in pin-holed pans were 283 
scanned using the following heating cycles: a) ramp at 5°C min-1 from 25 to 220°C, b) ramp 284 
cooling at rate of 10°C min-1 from 220°C to zero 0°C min-1) ramp at 5°C min-1 from zero 0°C 285 
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back to 220°C. 286 
 287 
2.13. Scanning electron microscopy (SEM) 288 
Surface morphology of the film samples was examined by an ultra-high resolution Hitachi 289 
SU8030 SEM (Berkshire, UK). Each sample was sputter coated using chromium for 120 sec 290 
at 1 kV and 25 mA (EmiTech K575X Sputter Coater). Sputter coating of the samples is required 291 
prior to SEM imaging to prevent charging of the specimen and to increases the number of 292 
secondary electrons that can be detected from the surface of the specimen i.e. increases the 293 
signal to noise ratio. Chromium coating was used due to extremely thin nature of the films as 294 
well as being more economical than gold coating. Chromium is essentially used in high-295 
resolution analysis of thin layers as it produces a very smooth coating, giving exceptionally 296 
small grains and an even distribution of chromium nuclei in the coating layer (Stokroos et al., 297 
1997). The SEM images were acquired at an accelerating voltage of 20 kV and working 298 
distance of 15 mm, which were then processed with i-scan2000 software. A Hitachi SU8030 299 
cold FEG-SEM with Thermo Fisher Scientific -NORAN System and 7 Ultra-Dry X-ray 300 
detectors was used for semi-quantitative energy-dispersive X-ray (EDX) analysis to identify 301 
any observed particles on the surface of the films. EDX data were collected at an accelerating 302 
voltage of 8 kV. 303 
 304 
2.14. X-ray diffraction (XRD) 305 
The physical form (crystalline or amorphous) of the formulations and starting materials was 306 
determined using a D8 Advantage Bruker X-ray diffractometer (Bruker AXS GmbH, Karlsure, 307 
Germany) equipped with a Goebel mirror with exit slits of 0.6 mm and a Lynx eye detector. 308 
Since the films are considerably thin, they were folded when placed in the sample holder to 309 
ensure maximum amount of sample was available and exposed to X-ray beam for more 310 
accurate evaluation. The transmission diffractograms were acquired using a DIFFRAC plus 311 
XRD Commander over a diffraction angle range of 5°- 50° 2θ, step size of 0.04° and scan speed 312 
of 0.2 sec per step. The operating conditions during the experiment were 40 kV and 40 mA 313 
with Cu Kα radiation. The data was processed with EVA software.   314 
 315 
2.15. In vitro drug release  316 
Sampling for in vitro drug release studies was carried out using an automated Gilson FC204 317 
fraction collector system (Middleton, USA) coupled with Thermo Fisher SC100 immersion 318 
circulators (Loughborough, UK) at 37 °C and Longer Pump BT100-1L multi-channels 319 
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peristaltic pump (Hebei, China). All formulations were tested simultaneously with STF running 320 
through the samples at constant flow rate of 50 L min-1, thus keeping the samples under sink 321 
condition throughout the experiment. The entire system as well as the STF bank was kept at 37 322 
°C.  STF was pumped into the chamber containing the sample from one end and flowed out of 323 
the chamber into the collector at the opposite end. This automated sampling technique at the 324 
given flow rate was set to mimic the tear turnover in the eye. Once the dissolution medium was 325 
collected at specified time intervals, the samples were placed in high-performance liquid 326 
chromatography (HPLC) vials and analyzed using an Agilent Technologies 1200 HPLC 327 
instrument (Cheshire, UK). Release of TM from the films was detected using a 150× 4.6 mm, 328 
5 µm reversed phase Spherisorb S5 ODS1 column (Deeside Ind., Clwyd, UK) with methanol 329 
(80): water (20): trimethylamine (TEA) (0.2) as the mobile phase, 1 mL min-1 flow rate and 330 
UV detection at a wavelength of 259 nm (adapted from Rodriguez et al., 2017).  331 
 332 
2.16. Cytotoxicity and cell viability 333 
In vitro cytotoxicity evaluation of the films was carried out using HeLa cells supplied by the 334 
Tissue Culture Laboratory of the University of Greenwich (Richardson Lab, School of 335 
Science, Grenville Building, University of Greenwich at Medway, Kent). In this study, 336 
cytotoxicity test was performed by indirect contact of the samples with the cells (Ahmed and 337 
Boateng 2018). Cells were cultured in Dulbecco’s Modified Eagle’s Medium supplemented 338 
with 10% fetal bovine serum and 1% penicillin-streptomycin (all from Thermo Fisher 339 
Scientific, Loughborough, UK). Cells were cultured until 70–80% confluence and challenged 340 
by formulations F1-F4. Films were cut into small disks using a 6 mm hole punching device 341 
and left under UV radiation for 24 hrs for sterilization. The samples were then immersed in 342 
1.5 mL of complete medium (mentioned above) for 24 hrs in a Heracell 150i CO2 incubator 343 
(Thermo Fisher Scientific, Dartford, UK) at 37 ºC. The dissolved samples in liquid state were 344 
filtered through a 0.2 μm filter and the filtrate collected. The cell suspension for the 345 
experiment was prepared at a concentration of 1×105 cells per mL and 100 µL of cell 346 
suspension transferred into designated wells of 96-well tissue-culture microtiter plates. The 347 
plates were left in the incubator at 37 °C in 5% (v/v) CO2 for 24, 48 and 72 hrs. Evaluation of 348 
the in vitro cytotoxicity of the films based on cell viability was determined by the 3-(4,5-349 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. At each time point (i.e. 350 
24, 48 and 72 hrs) 10 µL of MTT reagent (Thermo Fisher Scientific, Loughborough, UK) 351 
was added to each well including blank and controls and left in the incubator for an additional 352 
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4 hrs. Media was then completely removed from all wells and replaced with 100 µL of 353 
dimethyl sulfoxide (DMSO) (Thermo Fisher Scientific, Loughborough, UK). The plates were 354 
returned to the incubator for 30 min and the absorbance recorded at 520 nm by a microtiter 355 
plate reader (Multiskan FC, Thermo Fisher Scientific, Loughborough, UK) equipped with 356 
SkanIt for Multiskan FC 3.1 software (Thermo Scientific, Loughborough, UK). Every 357 
experiment was carried out in triplicates (n = 3) and the percentage cell viability was 358 
calculated using equation 5; 359 
Cell viability (%) =  
𝐴𝑡−𝐴𝑏
𝐴𝑐−𝐴𝑏
× 100   (5)   360 
Where At, Ab and Ac are the absorbance of tested samples, blank (medium only) and negative 361 
control (untreated cells) respectively. 362 
 363 
2.17. Statistical analysis 364 
Statistical analysis of quantitative data in this study was performed using one-way analysis of 365 
variance (ANOVA) and t-test. The level of significance chosen was 0.05 with p values below 366 
0.05 considered significant and measurements are presented as mean (± standard deviation). 367 
 368 
3. Results and discussion 369 
Optimized ocular films prepared in this study using solvent casting method confirmed the film 370 
forming abilities of HA and HPMC and their potential benefits in ocular drug delivery. The 371 
initial visual examination demonstrated the ability of both polymers to produce strong 372 
transparent films which were flexible and easy to handle both as single polymer and composite 373 
formulations. The visual assessment of transparency showed optimum results for all 374 
formulations with F4 being slightly cloudy yet transparent overall, as shown by legibility of 375 
the underlying ruler in figure 1.  376 
3.1. Transparency 377 
  Transparency of the films was further confirmed by measuring the light transmittance 378 
using UV spectroscopy, and the overall response is illustrated in figure 2. As can be observed 379 
in the figure, almost all the formulations showed light transmission values above 80% in the 380 
visible light (400-700 nm) region. The lower percentage light transmittance of F4, 75.87 ± 381 
4.55, is suspected to be due to higher concentration of polymer in that formulation (table 1). 382 
Higher polymer concentration in F4 increases density of materials in the film (i.e. higher weight 383 
and thickness) which subsequently affected the transparency of this film as light transmission 384 
is directly affected by density of materials. This slight opacity of F4 in transmission of visible 385 
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light was also visually observable by looking through the film as shown in figure 1.  386 
  Further, transparency of the films was investigated by means of an in vivo human visual 387 
examination survey. The result for the volunteers and their score for each film confirms the 388 
results from the two previous transparency measurements discussed above. The average score 389 
for formulation F1 to F4 was 1.0, 1.0, 1.2 and 1.6 respectively. Though F4 was considered 390 
transparent, the degree of transparency was also judged by the volunteers to be slightly lower 391 
than other formulations.  392 
 393 
3.2. Physicochemical evaluation 394 
3.2.1 Weight and thickness 395 
Weight and thickness of the films increased with increase in polymer concentration. Both 396 
weight and thickness play key roles in certain characteristics such as swelling, tensile properties 397 
and drug release. Generally, the weight and thickness results were found within the standard 398 
range of commercially available contact lenses with F4 having the maximum accepted 399 
(Johnson & Johnson Acuvue standards) thickness of 0.09 mm (table 2). The higher thickness 400 
value of F4 is again due to the presence of higher concentration of polymer (w/v) in comparison 401 
with the other formulations (table 1).  402 
3.2.2 Surface pH 403 
The optimum pH of an ocular formulation is 7.2 ± 0.02, however, the buffering capacity of the 404 
tears allows the eyes to tolerate pH values in the 3.5-8.5 range (USP Forum 35-5; Imperiale et 405 
al., 2018). The pH range of the formulations in this study was 5.97 ± (0.08) to 6.46 (± 0.05) 406 
(table 2) which is within the accepted pH range for topical ocular administration and therefore 407 
not expected to cause any irritation when applied to the eyes.  408 
3.2.3 Folding endurance 409 
The flexibility of the polymeric thin films was measured with respect to their folding 410 
endurance. The results suggested excellent flexibility, with each film formulation remaining 411 
intact after more than 300 folding repeats. The flexibility of the films is critically important 412 
considering the fact that the ocular films will be handled by patients and need to be 413 
administered without breakage as well as not causing contact irritation or damage to healthy 414 
eye tissues due to brittleness. 415 
 416 
3.3. Swelling index study 417 
The swelling capacity was investigated to evaluate the hydrophilicity, hydration and erosion of 418 
the films, and the results are presented in figure 3. Both F1 and F3 swelled rapidly in the first 419 
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10 min with swelling index values of 2039.6% and 1767.9% respectively. Swelling of F2 and 420 
F4 films after 40 min was significantly lower (p < 0.05) than F1 and F3. Formulations 421 
containing higher ratio of HPMC i.e. F2 and F4 showed an overall lower swelling capacity 422 
compared to F1 containing only HA or F3 with equal ratios of HA:HPMC.  423 
The degree of swelling depends on the rate of penetration of fluid into the polymer 424 
matrix and the matrix resistance to movement of the water molecules within it and eventual 425 
erosion of the matrix. High molecular weight polymers such as HPMC (C56H108O30) normally 426 
produce physically stronger film sheets due to shorter distance between the polymer chains. In 427 
addition, due to presence of nitrogen in HA (C14H21NO11), an additional electronegative 428 
element in the repeating monomer, it forms secondary hydrogen bonds (in red, figure 4) which 429 
results in a stronger matrix despite the longer distance between polymer chains.  430 
 The molecular characteristics of the polymers play an important role in swelling capacity, erosion 431 
and hence the release of the drug from the film matrix. Though HPMC forms stronger films, the 432 
chemical bonds between the polymer chains are only supported by hydrogen bonding between its 433 
hydroxyl groups, which allows easy penetration of water inside the matrix, and even easier polymer 434 
chain disentanglement and relaxation. The polymer chains in HA containing films (F1, F3 and F4), on 435 
the other hand, are held more strongly by two types of hydrogen bonding, involving the N–H and O–436 
H groups which hold the matrix more tightly together despite the increase in distance between the 437 
polymer chains upon penetration of water. This results in ability to absorb and hold on to more water 438 
(i.e. higher swelling index) and to also delay the disentanglement of polymer chains and ultimately the 439 
release of any incorporated substances from the film matrix. This ability of HA to hold more water 440 
(confirmed by TGA results) also enhances the flexibility of HA (i.e. F1, F3 and F4) as water itself acts as 441 
a plasticizer within the film. In addition, HA and HPMC are completely amorphous materials and are 442 
easier to hydrate and erode compared to crystalline materials due to their irregular polymer–polymer 443 
bonds. It was reported by Adel and ElKasabgy that the presence of plasticizer in formulations affects 444 
the percentage of moisture absorbed. In addition to the water content, the films also contained 445 
plasticizer (i.e. GLY) which enhances flexibility of the films even more by reducing the glass transition 446 
temperature (Tg) (Adel and ElKasabgy, 2014). In general, polymers with high Tg often suffer from brittle 447 
behavior and low processability. 448 
3.4. Tensile properties 449 
The results obtained from stress/strain curve was used to calculate mechanical characteristics 450 
of the films which are presented in table 3. The tensile strength of formulations F1-F4 was 451 
within the range of 39.98 ± 11.71 to 166.33 ± 21.19 Nmm-2. The elastic modulus of all films 452 
was found to range between 1.01 ± 0.32 and 81.91 ± 16.25 mPa. F3 showed the lowest % 453 
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elongation 51.66 ± 0.81 while F1 showed the highest value of 72.53 ± 6.37. Generally, all films 454 
displayed a uniform correlation between stress and strain and produced typical curve of a 455 
material with ideal elastic behavior (Bhamra and Tighe, 2017).  456 
Tensile strength and elastic modulus results revealed formulations containing higher 457 
ratio of HPMC i.e. F2 and F4 produced considerably stronger films compared to F1 and F3. 458 
However, F1 (containing HA only) produced the most elastic film confirmed by the highest % 459 
elongation value 72.53 ± 6.37 amongst all formulations. Tensile strength and % elongation 460 
values were compared to that from Priya and co-workers (2014) study, where they produced 461 
films using HPMC, PVP and propylene glycol. Generally, both tensile strength and % 462 
elongation values of F1-F4 were higher than all the formulations in that study. Interestingly, 463 
the tensile strength of F2 and F4 were considerably higher than all films produced in the study 464 
by Priya et al. Further, the folding endurance results in their study, showed that the maximum 465 
folding endurance was 29, which indicates the films were considerably brittle compared to F1-466 
F4 in this study with folding endurance of >300.  467 
Water content of the films was considered to affect the elasticity and hence elongation 468 
values due to plasticizing effects of water within the film matrices. Tranoudis and Efron (2004) 469 
revealed no significant relationship between water content and mechanical properties of soft 470 
contact lenses. However, contact lenses are made from non-erodible hydrogels where presence 471 
of water does not necessarily influence the physical state of the hydrogel because the polymer-472 
polymer bonds are not affected by water molecules. In the case of the thin erodible ocular films 473 
prepared in this study, water content (confirmed by TGA) plays a major role in elasticity of 474 
films, as the polymer chains interactions are susceptible to water molecules as was also 475 
confirmed by swelling results. Another significant factor is polymer concentration which had 476 
direct correlation with weight, thickness and density of the films (table 2) and ultimately the 477 
mechanical properties of the films.  478 
  Strength and flexibility are both essential in ocular films because appropriate strength 479 
helps to prevent tearing due to stress generated by blinking action of the eye, and flexibility for 480 
ease of handling and application by the patient and to avoid irritation to the eye (Jethava et al., 481 
2014). Therefore, use of the two polymers within the composite films combines the physical 482 
advantages of each polymers i.e. strength of HPMC and flexibility of HA. 483 
 484 
3.5. In vitro mucoadhesion 485 
Evaluation of mucoadhesion properties of formulations F1-F4 are summarized in table 4. 486 
Formulation F2, containing HPMC only, showed the lowest stickiness (PAF), TWA and 487 
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cohesiveness amongst all the films. These values almost doubled in F1 (HA only formulation). 488 
Interestingly, the combination of the two polymers in the composite films (F3 and F4) enhanced 489 
PAF and TWA values compared to single polymer formulations. However, the difference in 490 
mucoadhesion properties of the films was not statistically significant (p > 0.05). F3 showed the 491 
most optimum mucoadhesion properties amongst all formulations (table 4).  492 
  In vivo adhesion of films to mucosal surfaces of the eye such as cornea or cul-de-sac is 493 
due to interaction of the polymeric thin films with the tear fluid, or more specifically the lipid-494 
rich layer (outermost layer) of the tear film which is partially composed of meibum produced 495 
by fully differentiated meibocytes in the holocrine meibomian glands. Despite variations in the 496 
published compositions, sterol esters and wax esters seem to be the most abundant lipid species 497 
in the meibum (Rantamäki et al., 2011). Although meibum lipids have been studied widely, 498 
comprehensive tear fluid lipidomic studies are lacking. However, in a neutral medium, the 499 
mucin molecules are negatively charged (pKa -2.6) and behave as anionic polyelectrolytes, 500 
forming a weak viscoelastic gel which consists of a network of linear, flexible and random coil 501 
molecules. Polymer–mucin interactions include chain interlocking, conformational changes 502 
and non-covalent bond formation (Chavda et al., 2016). Polymers such as HA and HPMC have 503 
functional groups that are able to form hydrogen bonds and the polymer chain are flexible 504 
enough to form as many intermolecular bonds as possible. 505 
  The enhanced mucoadhesion properties due to presence of HA is attributed to 506 
remarkable wettability and hydration of HA exhibiting strong non-covalent intermolecular 507 
interaction with the gelatin substrate which was used to mimic the mucosal surface of the eye 508 
(Ayensu et al., 2012; Nowak et al., 2015). Though the lipid-rich layer containing meibum (in 509 
an in vivo setting) was absent, spreading STF on the gelatin surface allowed us to simulate the 510 
ocular mucosa surface for in vitro mucoadhesion studies where the salts present in STF act as 511 
charged polyelectrolytes. However, the presence of esters in meibum could potentially increase 512 
the number of hydrogen bonding and Van der Waals interactions which would further enhance 513 
the adhesion of the films on the model mucosal surface. Once again, the presence of amine 514 
group in HA creates secondary intermolecular hydrogen bond interaction with chains of the 515 
hydrated gelatin surface which acts as additional force compared to HPMC, which only relies 516 
on hydrogen bonds of the hydroxyl group. In general, the initial stages of mucoadhesion 517 
involves physical contact of the film and the mucosal surface which results in hydration of the 518 
polymer, leading to formation of physical entanglement between the polymer and the gelatin 519 
substrate and establishing adhesive forces between the two interacting surfaces. Presence of 520 
salts (in STF) have also been reported amongst factors affecting the mucoadhesion properties 521 
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of polymer-based systems for topical mucosal applications (Khan et al., 2016). 522 
3.6. Sterilization 523 
It is a mandatory requirement for every formulation designed for topical ocular administration 524 
to be completely sterile and free of microorganisms to ensure their safety for patients. The most 525 
reliable sterilization method in the industry, based on International Pharmacopoeia (8th edition, 526 
2018, section 5.8), is exposure to saturated steam under pressure in an autoclave. This method 527 
is used to sterilize commercially produced TM eye drops. Other sterilization methods include 528 
gamma and ultraviolet (UV) radiation (Alariqi et al., 2016). During this study, the research 529 
team had no access to gamma radiation, and steam autoclave could not be used because of 530 
swelling of the hydrophilic films; therefore, UV radiation technique was used for sterilization. 531 
  Desai and co-workers (2018) attempted the autoclave sterilization approach and 532 
observed loss of dosage form during the sterilization process which subsequently affected the 533 
amount of drug available during drug release studies. They subsequently concluded that use of  534 
UV radiation an appropriate sterilization approach for polymer based ocular inserts (Desai et 535 
al., 2018). Sterilization by UV radiation is a simple, effective and cost-efficient method that 536 
has been shown to preserve biocompatibility of the sterilized materials. Short-wave UV 537 
irradiation (100-280 nm) causes disruption of DNA-based pairing leading to inactivation of 538 
bacteria, viruses and protozoa allowing sterilization of the samples (Rastogi et al., 2010). 539 
Though sterilization is aimed to improve the biocompatibility of the formulation, it can cause 540 
adverse effect on the performance of formulations and certain physicochemical properties, such 541 
as tensile strength and elongation (Galante et al., 2018 and Yeh et al., 2011). Therefore, the 542 
tensile and mucoadhesion properties of the sterilized ocular films were analyzed to investigate 543 
the potential effects of UV radiation on these mechanical characteristics of the films. 544 
Sterilization by UV radiation showed no significant effect (p > 0.05) on physical and 545 
mechanical properties of the films. The variation observed in the post-sterilization results 546 
showed no consistent pattern, and when compared to non-sterile films the difference was not 547 
statistically significant (p > 0.05). Assessment of results for tensile properties of single polymer 548 
formulations (F1 and F2) revealed only slight changes in the values after sterilization. Tensile 549 
strength value (N/mm2) of F1 reduced from 21.01 ± 4.64 to 18.66 ± 6.91 while its % elongation 550 
value increased from 0.98 ± 0.25 to 2.18 ± 1.52. In composite formulations, (F3 and F4), the 551 
% elongation decreased in both formulations from 51.66 ± 0.81 to 49.91 ± 1.15 and from 51.19 552 
± 12.33 to 49.41 ± 3.88, respectively. Tensile strength and elastic modulus of the composite F3 553 
and F4 films also showed no consistent pattern. Mucoadhesion results revealed general increase 554 
in stickiness of the films after sterilization, indicated by higher PAF values. Cohesiveness of 555 
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single polymer F1 and F2 films increased after sterilization while the composite F3 and F4 556 
formulations showed reduction in cohesiveness.  557 
  Taking standard deviation values into consideration, together with statistical analysis, 558 
the difference in results before and after sterilization is statistically insignificant. The non-559 
significant differences observed is suspected to be due to exposure of the films to air for 24 hrs 560 
during sterilization which can cause alterations in moisture content of the films and hence slight 561 
difference in mechanical properties. Loss of water can increase the tensile properties as the 562 
distance between the polymer chains reduces, while reducing the elasticity of the films, since 563 
water has known plasticizing effects.  564 
 565 
3.7. ATR FT-IR spectroscopy 566 
FTIR analysis is often used to show compatibility and interactions between different excipients 567 
within a formulation. Secondary interactions such as hydrogen bonding and van der Waals 568 
(induced dipoles) tend to increase the stability of structures which can be detected by shifts in 569 
wavelength in the FTIR spectra (Mehta et al., 2017). The FTIR spectra of the films (F1-F4), 570 
pure polymer powders and pure TM powder were assessed and compared to evaluate the drug-571 
polymer interaction in all formulations (figure 5) and to confirm the stability of TM in the film 572 
matrices. The FTIR spectrum of TM pure powder showed principal peaks at 2976 cm-1 and 573 
2892 cm-1 corresponding to stretching of hydroxyl group. The spectra of HA and HPMC 574 
powders are also presented in figure 5(b) together with the spectra of all physical mixtures. In 575 
addition, the absorption band due to bending of the amine group was observed as a shoulder to 576 
the main peak at 1698 cm-1 as shown in figure 5b below. The spectra of the physical mixture 577 
revealed no considerable changes when compared to FTIR peaks of TM, confirming no major 578 
physical interactions within the mixture. Evidently the drug-polymer interaction was also 579 
absent in the films as the principal peaks of incorporated TM in the films appeared in similar 580 
regions in the spectra of formulations F1-F4 with no major shifts observed, as shown in figure 581 
5(a).  582 
  For instance, in F1, the peaks at 2976 cm−1 and 2892 cm−1 due to stretching of –OH 583 
group in TM appeared at 2928 cm−1 and 2880 cm−1 adjacent to the –OH bend of the films which 584 
is due to water content available in formulations (confirmed by TGA results). Other principal 585 
peak of TM at 1698 cm−1 due to bending of –NH group in TM also appeared in the spectra of 586 
all formulations with negligible shifts in wavelength. The evaluation of ATR-FTIR results 587 
confirms the stability of TM in the formulations developed in this study with no major drug-588 
polymer interaction. 589 
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 590 
3.8. IR microscopy and imaging 591 
Distribution of TM in formulations F1-F4 was investigated and confirmed by mapping the 592 
availability of TM across the four films using an IR microscope. Presence of TM across the 593 
film was monitored using density of the principal peaks of TM which were previously 594 
identified and confirmed by ATR-FTIR results i.e. 2976, 2892 and 1698 cm-1. Figure 6 595 
illustrates the IR mapping results using F1 as a representative formulation which includes the 596 
3D map of the film (top), the density map of absorption (middle) and the evaluated IR peaks 597 
(bottom). The results suggest 40-60% (green) presence of TM across the film (3D map) with 598 
minor areas containing less than 30% (amber and red) present. Occasional appearance of blue 599 
spots in the map indicates areas with TM density of above 70% but these only appeared in a 600 
few instances. This indicates higher density of drug particles in those areas compared to areas 601 
appearing in green. Formulations F2-F4 also showed similar results to F1 with adequate 602 
uniform distribution of TM across the film. An ideal IR map must show even density (40-60%) 603 
of drug molecules across the film indicated by green color for principal peaks. For improved 604 
distribution, the time for gelation and mixing process could be extended with higher stirring 605 
speed to ensure the drug molecules are more evenly distributed.  606 
3.9. Thermogravimetric analysis (TGA) 607 
Residual moisture content of the films was determined by TGA. Formulation F1 with 8.68% 608 
and F2 with 5.96% showed the highest and lowest moisture content, respectively, amongst all 609 
films. Despite the effect of GLY on moisture content which was reported by Ahmed and 610 
Boateng (2018), the structure of each polymer and their ability to absorb water play an 611 
important part in moisture content of the prepared formulations. F1 containing only HA, had 612 
the highest % moisture content which again confirms the exceptional hydration characteristic 613 
of this polymer, as was observed during swelling studies (figure 3) due to its hydrophilic nature. 614 
The ability of HA to absorb water molecules is due to presence of amine group (not present in 615 
HPMC) which provides additional intermolecular polymer-polymer interaction, allowing the 616 
water molecules to remain between the polymer chains without collapse of the film matrix 617 
structure. Percentage moisture content in F3 and F4 evidently support this characteristic of HA. 618 
F3 containing 1:1 ratio of HPMC:HA showed higher % moisture content, (7.54%), compared 619 
to F4, (6.72%). The moisture content of 7.54% in formulation F3 was also higher than that in 620 
formulation F2 (5.96%) which contained only HPMC, again demonstrating the impact of HA 621 
in the films holding on to more moisture compared to HPMC. Furthermore, F4 containing 622 
higher ratio of HPMC with ratio of HPMC:HA 3:1, showed lower % moisture content 623 
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compared to F3 but higher value compared to F2 which again support the higher moisture 624 
holding capacity of HA.  625 
 626 
3.10. Modulated differential scanning calorimetry (MDSC) 627 
DSC analysis was used to characterize the thermal behavior of pure TM and its physical state 628 
when incorporated within formulations F1-F4. HPMC and HA are both predominantly 629 
amorphous polymers and typically expected to exhibit a phase transition at specific temperature 630 
threshold known as glass transition temperature (Tg). Absence of Tg was expected for HA as 631 
previous DSC analysis of this polymer also showed no clear Tg (Ravari et al, 2016; Abdelkader 632 
et al., 2016). Jadhav and colleagues reported Tg of HPMC at 180 °C. However, the DSC 633 
thermogram of HPMC powder used in this study showed Tg between 125-137 °C followed by 634 
distinct endothermic thermal event at 164.21 °C. This is fundamentally based on different 635 
grades of this polymer (i.e. molecular weight) [the HPMC grade was not specified in the above-636 
mentioned study].  Furthermore, no clear Tg was observed in the thermograms of the films 637 
(figure 7b). The exothermic peak in F1 is typical for HA, normally observed between 200-230 638 
°C and corresponds to crystallization of HA. This peak was observed in the thermogram of 639 
pure polymer powder, as a shoulder to the large endothermic peak at 205.77 °C (likely due to 640 
trace components such as sulfate linked with glycosaminoglycan), but shifted to around 160 641 
°C (figure 7b) in the HA only film (F1) as the polymer undergoes further amorphization during 642 
film formation due to presence of GLY and residual water content (Adel and ElKasabgy, 2014). 643 
DSC thermogram of pure TM displayed typical thermogram of a crystalline substance with a 644 
single sharp endothermic peak at 205.11°C corresponding to its melting point (figure 7a). The 645 
sharp characteristic peak of TM was absent in DSC thermograms of formulations F1-F4 646 
indicating the suppression of TM crystallinity in the films. This amorphization of the drug also 647 
suggests distribution and molecular dispersion of TM within the film matrices. In general, 648 
amorphous drugs exhibit better solubility and therefore more rapid release advantage over the 649 
more stable crystalline equivalent, however, they have the tendency to convert back to the 650 
stable crystalline form and must therefore be stored appropriately.  651 
 652 
3.11. Scanning electron microscopy (SEM) 653 
The SEM micrographs of all the films revealed general smoothness of the surface as 654 
demonstrated in figure 8. Considering the high sensitivity of the eye, it is crucial that the ocular 655 
films aimed for topical administration are completely smooth and causes no irritation for the 656 
patient. Occasionally, small particles appeared sparsely on the surface of some films in various 657 
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batches of different formulations; for instance, single small particle could be observed on the 658 
surface of F3 (figure 8).  After chemical analysis of these particles by semi-quantitative EDX 659 
at 8 kV accelerating voltage, they appear to be mainly entangled polymers identified by high 660 
carbon (64.9 ± 0.7 %) and oxygen content (34.1 ± 2.1 %) in their molecular structure. 661 
Negligible amount of aluminium (1.0 ± 0.3 %) was detected by EDX which is due to X-ray 662 
going through the thin and transparent film samples and reaching the aluminium stub. 663 
 664 
3.12. XRD 665 
The diffraction patterns of TM powder revealed numerous sharp and high intensity peaks 666 
between diffraction angles range of 10° to 30° 2θ, confirming the crystallinity of TM powder 667 
a shown in the DSC results. HPMC and HA powders exhibited halo diffraction patterns which 668 
confirm their amorphous nature. Generally, the diffractograms of formulations F1-F4 showed 669 
halo diffraction pattern which indicates amorphization of the drug and its molecular 670 
distribution in the film matrices. This supports DSC and IR microscopy results confirming the 671 
molecular dispersion of TM throughout the films. A sharp peak appeared initially in the 672 
diffractograms of F1-F4 at 23° 2θ similar to HPMC containing formulations reported by of 673 
Okeke and Boateng (2016). After further evaluation of various formulations including blank 674 
and unplasticised films, the peak was determined to be a response to the plastic sample holder 675 
of the specimen during sample analysis. After removing the plastic part of the specimen holder 676 
the peak disappeared and the expected halo diffraction pattern of amorphous film was observed 677 
(figure 9).  678 
 679 
3.13. In vitro drug release  680 
In vitro - in vivo correlation (IVIVC) of drug release, permeation and efficacy of TM at known 681 
concentrations has been investigated by many scientists including Shafie and Rady (2012), 682 
Korogiannaki et al (2015), Thakral et al (2015) and Desai et al (2018). TM has been the first 683 
line treatment for glaucoma for many years and there are many studies available which have 684 
used TM as the model drug, since its therapeutic efficacy is well-known. However, the 685 
challenges associated with more effective delivery of TM still exist as eye drops (ophthalmic 686 
solutions) are still the only dosage form available for topical delivery of TM. Conventionally, 687 
maximum TM dosage is one drop of 0.5% w/v applied in the affected eye twice daily (total 688 
dose of 400 µg in 24 hrs) which provides plasma concentrations of approximately 0.5 ng ml-1, 689 
based on a study which used healthy volunteers (Gray, 2006). More importantly dosages above 690 
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one drop of 0.5% w/v TM ophthalmic solution twice a day generally have not been shown to 691 
produce further reduction in IOP (Bauch & Lomb Timoptic®).  692 
In this study, 0.5% w/v dose of TM was incorporated into the gels prior to film 693 
formation volume. The film disks used for in vitro drug release studies contained the following 694 
total available dose for formulations F1 to F4, respectively: 196 µg, 160 µg, 129 µg and 227 695 
µg. Figure 10 shows the in vitro cumulative release profiles of the TM loaded ocular films F1-696 
F4 using an automated flow cell. The flow rate (50 µL min-1) was the lowest on the machine 697 
and closest to the tear turnover rate in human eyes (0.5 - 2.2 µL min-1) or total tear volume in 698 
a healthy eye (7 - 9 µL) (Bachu et al., 2018) which could produce sufficient volume of 699 
dissolution medium for in vitro analysis of drug release. F1 showed highest cumulative release 700 
of 71.59% (140.32 µg) whilst F4 showed the lowest with 41.48% (94.16 µg) release. The films 701 
containing HA i.e. F1, F3 and F4 reached maximum cumulative drug release in 8 hrs which 702 
shows remarkable ability of HA to delay the polymer chain disentanglement and therefore 703 
slows down rate of drug diffusion from the swollen matrix resulting in a prolonged release 704 
pattern of the drug from these formulations. However, F2 reached maximum cumulative drug 705 
release within only 2 hrs, which is due to rapid swelling and erosion rate. This result is in 706 
agreement with the swelling index study where F1, F3 and F4 (in order) showed prolonged 707 
swelling and delayed erosion compared with F2 which swelled more rapidly and eventually 708 
disintegrated.  709 
Calles and colleagues investigated TM release from cross-linked ocular films and 80% TM was 710 
released in the first 2 hrs of study (Calles et al., 2013). In another study by Mehta and co, TM 711 
was used in polymeric contact lens coating, and 75% TM was released within 6 hrs (Mehta et 712 
al., 2017). The ability of HA to delay the release of TM in F1, F3 and F4 of this study shows 713 
potential of this polymer for controlled ocular drug delivery purposes in the form of thin films.  714 
The flow rate of STF over the samples in this study (50 µL min-1) is considerably higher than 715 
usual tear turnover rate in the eye (1.2 µL min-1) or total tear volume in the ocular cavity (7-10 716 
μL); therefore, the release of drug from the formulations in this study is expected to be even 717 
more prolonged in an in vivo setting. This was also confirmed by the in vivo study carried out 718 
by Desai and colleagues. In this study, the poor IVIVC observed was due to the differences 719 
between the in vivo and in vitro release conditions and more specifically the dissolution volume 720 
under sink conditions. In their in vitro study, the formulation was placed in 2 mL of STF 721 
dissolution media, whereas in the animal study, the formulation was exposed to just 7–10 μL 722 
of the tear volume in the ocular cavity. A markedly high release of TM was observed under the 723 
in vitro release conditions, whereas a lower (2-fold) release amount was observed in the rabbit 724 
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tear fluid (Desai et al., 2018). Therefore, the release of TM from erodible thin ocular films in 725 
this study is also expected to be more prolonged during the in vivo studies where the tear 726 
volume and turnover rate is significantly lower. Therefore, despite the low thickness, the HA-727 
containing formulations developed in this study, have the ability to deliver up to 71% of the 728 
dose (≈140.32 µg) in a controlled release pattern, within 8 hours. However, the concentration 729 
of the drug in each formulation needs to be increased to reach the required 400 µg dose a day 730 
before proceeding to in vivo testing of these ocular films in future work. 731 
Further, mechanism and kinetics of drug release from the films were calculated according to 732 
Korsmeyer-Peppas model, which describes the release behavior of drug from polymeric 733 
systems which is related to the erosion and dissolution of the polymer matrix (Korsmeyer et 734 
al., 1983). 735 
𝑄𝑡
𝑄∞
= 𝑘𝑡𝑛    (6) 736 
 737 
Where Qt/Q∞ is the cumulative percent release, k is Korsmeyer-Peppas constant, t is the release 738 
time and n the release exponent for the drug. Korsmeyer-Peppas stated that the above equation 739 
could adequately describe the release of solutes from slabs, spheres, cylinders and discs, 740 
regardless of the release mechanism. 741 
The value of ‘n’ gives an indication of the release mechanism; when n = 1, the release rate is 742 
independent of time (zero-order) (case II transport), n = 0.5 represents Fickian diffusion, n < 743 
0.5 indicates that the release rates exhibit a combined mechanism of diffusion partially through 744 
a swollen matrix and partially through water-filled pores and when 0.5 < n <1.0, diffusion and 745 
non-Fickian transport are implied, while n values > 1.0 implies super case II transport. The 746 
release exponent, n, is the slope value of log Qt/Q∞ versus log time curve. Slope values 747 
presented in table 5 showed values of 0.5 < n < 1.0 for F1 to F4 which suggests that the release 748 
of TM from all formulations followed non-Fickian diffusion mechanism.  749 
 750 
3.14. Cytotoxicity and cell viability  751 
Assessment of cytotoxicity is vital for any materials that come into contact with the ocular 752 
surface. Formulations F1-F4 were applied to HeLa cell lines for cytotoxicity evaluation of the 753 
films. The polymers used in this study are currently being used in many pharmaceutical 754 
formulations and are listed as GRAS by FDA. The MTT assay in this study investigated blank 755 
single polymer HA (F1) and HPMC (F2) film as well as F3 and blank F3. The results (figure 756 
11) revealed high % cell viability of polymers and the TM loaded films over 72 hrs. Generally, 757 
24 
 
the accepted % cell viability is expected to be > 70% according to the ISO specification (Ahmed 758 
et al., 2018) and all the formulations tested (both blank and TM loaded) show cell viability 759 
values above 70% which confirm their suitability for direct application to the ocular surface 760 
for up to 72 hrs. 761 
 762 
4.0. Conclusion 763 
The results obtained in this study reveal that HA and HPMC can produce optimum ocular films 764 
either as single polymer or in composite matrix. However, incorporating both polymers within 765 
a composite formulation can combine the strong film forming ability of HPMC with the 766 
remarkable swelling capacity of the HA. The strong amino and hydroxyl group in HA was 767 
shown to play a major role in its ability to absorb and retain water molecules for longer period, 768 
which allows prolonged drug release profiles. The drug loaded films were generally 769 
biocompatible with cell viability results falling within the expected standard. Overall, 770 
composition of HA and HPMC have enhanced characteristics compared to single polymer 771 
formulations and is a promising delivery system for topical delivery of TM for potential 772 
treatment and management of glaucoma, and this will be further evaluated using an in vivo 773 
animal study in future work.  774 
 775 
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TABLES 904 
 905 
Table 1. Formulation (gel) composition of each film in 100 mL of water. All gel 906 
formulations were loaded with 0.5% w/v of TM prior to drying in oven.  907 
 Composition in 100 mL twice-distilled water 
Formulation HPMC (mg) HA (mg) GLY (mg) TM (mg) 
F1 ─ 1000 500 7.50 
F2 1500 ─ 750 11.25 
F3 500 500 500 7.50 
F4 500 500 1000 15.00 
 908 
Table 2. Weight, thickness, surface pH and folding endurance results of formulations F1-909 
F4 (n = 3).  910 
TIM-loaded 
Film 
Weight (g) 
(±SD) 
Thickness (mm) 
(±SD) 
Surface pH 
(±SD) 
Folding Endurance 
(±SD) 
F1 0.10 ± 0.01 0.04 ± 0.01 5.97 ± 0.08 > 300 
F2 0.12 ± 0.02 0.07 ± 0.03 6.46 ± 0.05 > 300 
F3 0.09 ± 0.01 0.06 ± 0.01 6.05 ± 0.07 > 300 
F4 0.17 ± 0.03 0.09 ± 0.01 6.01 ± 0.03 > 300 
 911 
  912 
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Table 3. Tensile properties of formulations F1-F4 (n = 3). 913 
TIM-loaded 
Film 
Tensile Strength (N/mm2) 
±SD 
Elastic Modulus (mPa) 
±SD 
Elongation (%) 
±SD 
F1 21.01 ± 4.64 0.98 ± 0.25 72.53 ± 6.37 
F2 198.97 ± 17.31 4.80 ± 1.23 58.01 ± 9.12 
F3 49.72 ± 5.42 2.38 ± 0.23 51.66 ± 0.81 
F4 149.07 ± 21.93 5.38 ± 0.69 51.19 ± 12.33 
 914 
 915 
Table 4. Mucoadhesion properties of formulations F1-F4 (n = 3). 916 
TIM-loaded Film PAF (N) TWA (N/s) Cohesiveness (mm) 
F1 1.66 ± 0.42 1.76 ± 0.54 6.49 ± 1.13 
F2 0.98 ± 0.06 0.58 ± 0.05 1.79 ± 0.33 
F3 3.79 ± 0.43 5.85 ± 0.53 5.22 ± 0.36 
F4 3.47 ± 0.61 3.84 ± 0.55 5.38 ± 0.50 
 917 
 918 
Table 5. In vitro slopes and regression values from the Korsmeyer-Peppas kinetic model. 919 
TM-loaded Film R2 n 
F1 0.996 0.797 
F2 0.996 0.683 
F3 0.996 0.853 
F4 0.997 0.898 
 920 
  921 
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FIGURES 922 
 923 
Figure 1. Digital images of the ocular films (F1-F4) against a numbered ruler as part of visual 924 
assessment of transparency.  925 
 926 
 927 
Figure 2. Transmittance spectra (ultraviolet (UV)-visible range) for the tested 928 
formulations F1-F4. 929 
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  930 
Figure 3. Swelling profiles of the formulations F1-F4 (mean ± SD, n=3). 931 
 932 
 933 
 934 
 935 
Figure 4. Molecular interaction schematic of HPMC (left) and HA (right) polymer 936 
chains illustrating additional hydrogen bond in HA matrix due to presence of nitrogen 937 
(as indicated in red).   938 
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  940 
 941 
 942 
Figure 5. FTIR spectra of the (a) films and (b) TM, polymer powders and physical 943 
mixture. 944 
 945 
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 946 
 947 
 948 
 949 
35 
 
 950 
 951 
Figure 6. 3D map (top), 2D map (middle) and IR spectra (bottom) of F1 as representative result, 952 
illustrating the distribution of TM in the film. 953 
  954 
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 955 
956 
Figure 7. MDSC thermograms of (a) TM powder and (b) formulations F1-F4. 957 
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 958 
 959 
 960 
 961 
 962 
Figure 8. SEM micrographs of formulations F1-F4 showing their surface morphology. 963 
  964 
38 
 
965 
 966 
 967 
Figure 9. XRD diffractograms of (a) TM and polymers’ pure powder and (b) formulations F1-968 
F4. 969 
 970 
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 971 
 972 
Figure 10. Drug dissolution profiles showing percentage cumulative drug release against time for 973 
formulations F1-F4. 974 
 975 
 976 
 977 
 978 
Figure 11. Cell viability of HeLa cells after exposure to the extracts of blank HA film, 979 
blank HPMC film, TM loaded composite film (F3) and blank (no TM) F3 films for 24, 48 980 
and 72 hrs (mean ± SD, n = 6). 981 
 982 
0
10
20
30
40
50
60
70
80
90
0 60 120 180 240 300 360 420 480
%
 C
u
m
u
la
ti
v
e 
D
ru
g
 R
el
ea
se
Time (min)
F1 F2 F3 F4
0
20
40
60
80
100
120
24 hrs 48 hrs 72 hrs
%
 V
ia
b
ili
ty
Blank HA film Blank HPMC film Blank F3 F3
